Related Experiment Video
Updated: Sep 20, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Beyond Herceptin and Gleevec
Oliver M Fischer1, Sylvia Streit, Stefan Hart
1Max-Planck-Institute of Biochemistry, Department of Molecular Biology, Am Klopferspitz 18A, D-82152 Martinsried, Germany.
Abstract:
Identification of the key role of protein kinases as potential oncoproteins has led to the emergence of a new era of target-directed therapies. Among a variety of novel therapeutic strategies two have shown the most promise and led to a variety of therapeutic agents in clinical development. One approach utilises humanised monoclonal antibodies generated against the extracellular domain of transmembrane protein kinases. The second approach is the generation of small molecule ATP analogues targeting the kinase domain itself. The approval of agents such as Herceptin for the treatment of advanced breast cancer and Gleevec for chronic myelogenous leukemia and gastrointestinal stromal tumours are the first examples of gene-based cancer drugs and represent the first example of a novel strategy in anti-cancer therapy.
Insights
Protein kinases are key cancer targets. Novel therapies, including monoclonal antibodies and small molecule ATP analogues, are emerging for targeted cancer treatment, offering new hope for patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Protein kinases play a crucial role as oncoproteins in cancer development.
- Target-directed therapies represent a significant advancement in cancer treatment.
Purpose of the Study:
- To review novel therapeutic strategies targeting protein kinases.
- To highlight the clinical development of agents targeting protein kinases.
Main Methods:
- Development of humanized monoclonal antibodies against extracellular domains of transmembrane protein kinases.
- Generation of small molecule ATP analogues targeting the kinase domain.
Main Results:
- Successful clinical development of targeted therapies.
- Approval of Herceptin for breast cancer and Gleevec for leukemia and GIST.
Conclusions:
- Targeted therapies represent a novel and promising strategy in anti-cancer therapy.
- These advancements signify a new era in personalized cancer medicine.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers